CoChat

Mechanism of glucagon-like peptide 1 improvements in type 2 diabetes mellitus and obesity.

Nolen-Doerr, Eric, Stockman, Mary-Catherine, Rizo, Ivania · 2019 · Current Obesity Reports

The DOI matches its Crossref record; 98 of the 98 references it cites were found in a registry or an index.

Abstract

Purpose of review The purpose of this review is to emphasize the pivotal role of glucagon-like peptide 1 (GLP-1) in tackling the parallel epidemics of obesity and type 2 diabetes (T2DM).Recent findings GLP-1-based therapies and in particular GLP-1 receptor agonists (GLP-1 RA) have proven to be effective in lowering blood glucose and decreasing weight. GLP-1 RA not only mitigate these significant medical burdens but also result in weight loss and weight loss independent factors that decrease cardiovascular disease (CVD) and microvascular complications of T2DM, such as diabetic nephropathy. GLP-1-based therapies are critical for a patient-centered approach in choosing appropriate pharmacotherapy for T2DM and obesity while also taking into consideration comorbidities, such as cardiovascular and chronic kidney diseases.

Overview

Integrity signals

Registry

Crossref · 10.1007/s13679-019-00350-4

Cites

98 of 98 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 98 references

Cited by

See all 40

Metadata

Authors
Nolen-Doerr, E., Stockman, M.-C., & Rizo, I.
Affiliations
Boston University (US)
Corresponding author
  • Stockman, Mary-Catherine
  • Rizo, Ivania
Venue
Current Obesity Reports
Published
2019-05-23
Volume
8
Issue
3
Pages
284-291
ISSN
2162-4968 (ISSN-L)
OpenAlex
W2945534172
Cited by
32
References
98
Citations by year
2026: 3 · 2025: 3 · 2024: 6 · 2023: 3 · 2022: 2 · 2021: 8 · 2020: 4 · 2019: 2
FWCI
0.62
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Current Obesity Reports (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
Keywords
glucagon-like peptide-1, GLP-1 receptor agonists, type 2 diabetes, obesity, weight loss, glycemic control, cardiovascular disease, diabetic nephropathy, microvascular complications, chronic kidney disease, pharmacotherapy
MeSH terms
Glucagon-Like Peptide-1 Receptor, Animals, Blood Glucose, Cardiovascular Diseases, Cardiovascular System, Diabetes Mellitus, Type 2, Humans, Obesity, Weight Loss, Renal Insufficiency, Chronic, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Mechanism of glucagon-like peptide 1 improvements in type 2 diabetes mellitus and obesity. https://app.cochat.ai/papers/10.1007/s13679-019-00350-4
The paper
Nolen-Doerr, E., Stockman, M.-C., & Rizo, I. (2019). Mechanism of glucagon-like peptide 1 improvements in type 2 diabetes mellitus and obesity. Current Obesity Reports. https://doi.org/10.1007/s13679-019-00350-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.